315 related articles for article (PubMed ID: 33278600)
1. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
Cottereau AS; Meignan M; Nioche C; Capobianco N; Clerc J; Chartier L; Vercellino L; Casasnovas O; Thieblemont C; Buvat I
Ann Oncol; 2021 Mar; 32(3):404-411. PubMed ID: 33278600
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumor volume and lesion dissemination from baseline PET/CT in patients with diffuse large B-cell lymphoma: Further risk stratification of the group with low-risk and high-risk NCCN-IPI.
Xu H; Ma J; Yang G; Xiao S; Li W; Sun Y; Sun Y; Wang Z; Zhao H
Eur J Radiol; 2023 Jun; 163():110798. PubMed ID: 37030099
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
6. Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.
Girum KB; Cottereau AS; Vercellino L; Rebaud L; Clerc J; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
J Nucl Med; 2024 Feb; 65(2):313-319. PubMed ID: 38071535
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
8.
Cottereau AS; Nioche C; Dirand AS; Clerc J; Morschhauser F; Casasnovas O; Meignan M; Buvat I
J Nucl Med; 2020 Jan; 61(1):40-45. PubMed ID: 31201248
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of Dmax and %ΔSUVmax of
Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z
BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837
[TBL] [Abstract][Full Text] [Related]
10. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
11. Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome.
Wang F; Cui S; Lu L; Shao X; Yan F; Liu Y; He B; Wang J; Cao Y; Yue Y; Wang Y; Gu W
BMC Cancer; 2023 Nov; 23(1):1165. PubMed ID: 38030989
[TBL] [Abstract][Full Text] [Related]
12.
Girum KB; Rebaud L; Cottereau AS; Meignan M; Clerc J; Vercellino L; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
J Nucl Med; 2022 Dec; 63(12):1925-1932. PubMed ID: 35710733
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL.
Zhao P; Yu T; Pan Z
Ann Nucl Med; 2021 Jan; 35(1):24-30. PubMed ID: 33001389
[TBL] [Abstract][Full Text] [Related]
14. A nomogram for predicting the rapid progression of diffuse large B-cell lymphoma established by combining baseline PET/CT total metabolic tumor volume, lesion diffusion, and TP53 mutations.
Liu C; Shi P; Li Z; Li B; Li Z
Cancer Med; 2023 Aug; 12(16):16734-16743. PubMed ID: 37366281
[TBL] [Abstract][Full Text] [Related]
15. New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT.
Cottereau AS; Meignan M; Nioche C; Clerc J; Chartier L; Vercellino L; Casasnovas O; Thieblemont C; Buvat I
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439152
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of baseline
Xia L; Li X; Zhu J; Gao Z; Zhang J; Yang G; Wang Z
Radiat Oncol; 2023 Feb; 18(1):41. PubMed ID: 36829219
[TBL] [Abstract][Full Text] [Related]
17. [
Xu HQ; Song LJ; Ding CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
[TBL] [Abstract][Full Text] [Related]
18. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic Value of
Su JM; Zheng QZ; Huang WR; Deng J; Wu J; Lu HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1181-1186. PubMed ID: 34362500
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
[Next] [New Search]